Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYTOPREV: Immuno-guided CMV Prevention in Renal Transplant
NCT05708508Phase 3Recruiting
- Sponsor
- Rouen University Hospital
- Start
- Mar 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Incidence of CMV infection at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05708508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05708508.